A new review assessing clinical trial data on the treatment and management of children with juvenile idiopathic arthritis (JIA) found moderate evidence that those who respond to biologic disease-modifying antirheumatic drugs (DMARDs) are less likely to experience a flare of symptoms. But the review found few data on the relative safety and effectiveness of DMARDs, drugs that interfere with the development or function of immune cells.
The review (http://tinyurl.com/44asbyt), by the Agency for Healthcare Quality and Research, examined the benefits and harms of biologic and nonbiologic DMARDs compared with each other and with conventional treatments (which the review defined as nonsteroidal anti-inflammatory drugs and/or intra-articular corticosteroids) given with or without the nonbiologic DMARD methotrexate.
Hampton T. Review Sizes Up Therapies for Juvenile Arthritis. JAMA. 2011;306(17):1852. doi:10.1001/jama.2011.1571